Core Viewpoint - The company plans to invest 50 million yuan of its own funds to establish a joint venture, Hunan Jiutian Shanno Innovative Pharmaceutical Technology Co., Ltd., with two partners, enhancing its capabilities in innovative drug development and related technologies [1] Investment Details - The registered capital of the new company is set at 100 million yuan, with the company holding a 50% stake, Changsha Xiangjiang Shanno holding 30%, and Hainan Jiuzhi Qingyan Technology holding 20% [1] - This investment aims to accelerate the company's reserve and incubation of innovative drugs and technologies [1] Strategic Goals - The initiative is expected to cultivate new products and technologies that align with the company's core business, thereby enhancing its overall competitiveness and sustainable development capabilities [1] - The investment lays a solid foundation for the company's long-term healthy development [1]

Core Viewpoint - The company plans to invest 50 million yuan of its own funds to establish Hunan Jiutian Shanno Innovative Pharmaceutical Technology Co., Ltd. in partnership with two other firms [1] Group 1 - The registered capital of Hunan Jiutian Shanno is set at 100 million yuan, with the company holding a 50% stake [1] - Changsha Xiangjiang Shanno Venture Capital Partnership holds a 30% stake, while Hainan Jiu Zhi Qing Yan Technology Partnership holds a 20% stake [1] - This investment is classified as a related party transaction but does not constitute a major asset reorganization [1]

西部证券股份有限公司关于 （一）湘江善诺 1、基本注册信息 1 企业名称：长沙湘江善诺创业投资合伙企业（有限合伙） 湖南九典制药股份有限公司对外投资暨关联交易的核查意见 西部证券股份有限公司（以下简称"西部证券"或"保荐人"）作为湖南九 典制药股份有限公司（以下简称"九典制药"、"上市公司"或"公司"）向不特 定对象发行可转换公司债券持续督导的保荐人，根据《证券发行上市保荐业务管 理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》等相关法律法规、规范性文件要 求，对九典制药与对外投资暨关联交易事项进行了核查，具体核查情况如下： 一、对外投资暨关联交易概述 湖南九典制药股份有限公司（以下简称"公司"或"九典制药"）拟使用自 有资金 5,000 万元，与长沙湘江善诺创业投资合伙企业（有限合伙）（以下简称 "湘江善诺"）、海南玖智轻研科技合伙企业（有限合伙）（以下简称"玖智轻研"） 共同投资设立湖南九典善诺创新医药科技有限公司（暂定名，以工商登记核准为 准，以下简称"九典善诺"）。九典善诺注册资本为 10,000 万元，公司持股 50%， 湘江善 ...

湖南九典制药股份有限公司 | 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-074 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 关于对外投资暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、对外投资暨关联交易概述 湖南九典制药股份有限公司（以下简称"公司"或"九典制药"）拟使用自 有资金 5,000 万元，与长沙湘江善诺创业投资合伙企业（有限合伙）（以下简称 "湘江善诺"）、海南玖智轻研科技合伙企业（有限合伙）（以下简称"玖智轻 研"）共同投资设立湖南九典善诺创新医药科技有限公司（暂定名，以工商登记 核准为准，以下简称"九典善诺"）。九典善诺注册资本为 10,000 万元，公司 持股 50%，湘江善诺持股 30%，玖智轻研持股 20%。 因湘江善诺的有限合伙人包括公司及公司控股股东、实际控制人、董事长朱 志宏先生，玖智轻研的普通合伙人为公司控股股东、实际控制人、董事长朱志宏 先生控制的公司，所以本次对外投资事项构成关联交易，但不构成《上市公司重 大资产重 ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-073 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 第四届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 湖南九典制药股份有限公司（以下简称"公司"）第四届董事会第十三次会 议于 2025 年 10 月 23 日在公司 921 会议室以现场结合通讯会议的方式召开，会 议通知已于 2025 年 10 月 20 日以邮件方式送达。本次会议应出席的董事 7 人， 实际出席的董事 7 人（其中以通讯方式出席会议的董事有：杨洋先生、范朋云 先生、阳秋林女士、周从山先生、向静女士），全体监事、高级管理人员及保荐 代表人列席了会议，会议由董事长朱志宏先生召集并主持。本次会议的召开符 合有关法律、法规和《公司章程》的规定，形成的决议合法有效。 二、董事会会议审议情况 具体内容详见公司在巨潮资讯网上披露的《关于吸收合并全资子公司的公 告》。 表决结果：7 票同意，0 ...

| 证券代码：300705 | 证券简称：九典制药 | | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | 公告编号：2025-075 | 湖南九典制药股份有限公司 关于吸收合并全资子公司的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、吸收合并情况概述 为了优化资源配置，提高整体运营效率，湖南九典制药股份有限公司（以下 简称"公司"或"九典制药"）于 2025 年 10 月 23 日召开的第四届董事会第十 三次会议审议通过了《关于吸收合并全资子公司的议案》，拟以公司为主体吸收 合并全资子公司湖南汇阳信息科技有限公司（以下简称"汇阳信息"）。本次吸 收合并完成后，汇阳信息的法人资格将被注销，公司将依法承继其全部资产、债 权债务、合同关系等权利与义务。 本次吸收合并是在原合并报表范围内的合并，本事项不构成关联交易，也不 构成《上市公司重大资产重组管理办法》规定的重大资产重组。本次吸收合并不 涉及公司注册资本等事项的变更。根据《深圳证券交易所创业板股票上市规则》 和《公司章程》的相关规定，本次事项不涉及支 ...

Company Overview - Jiu Tian Pharmaceutical Co., Ltd. is located in Changsha High-tech Development Zone, Hunan Province, and was established on January 19, 2001. The company was listed on October 10, 2017. Its main business involves the research, production, and sales of pharmaceutical products [1] - The revenue composition of the company includes: 82.47% from pharmaceutical preparations, 7.65% from active pharmaceutical ingredients, 6.03% from pharmaceutical excipients, 3.16% from extracts and others, 0.63% from technology transfer and services, and 0.05% from other sources [1] Stock Performance - As of October 23, Jiu Tian Pharmaceutical's stock price decreased by 2.06%, trading at 16.67 CNY per share, with a market capitalization of 8.339 billion CNY. The stock has declined by 5.50% year-to-date and by 2.69% over the last five trading days [1] - The company experienced a net outflow of 8.7643 million CNY in principal funds, with significant selling pressure observed [1] Financial Performance - For the period from January to June 2025, Jiu Tian Pharmaceutical achieved a revenue of 1.512 billion CNY, representing a year-on-year growth of 10.67%. The net profit attributable to shareholders was 291 million CNY, reflecting a year-on-year increase of 2.57% [2] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 11.65% to 38,800, while the average number of circulating shares per person increased by 14.35% to 9,542 shares [2] - The company has distributed a total of 450 million CNY in dividends since its A-share listing, with 346 million CNY distributed over the past three years [3] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 7.0605 million shares, a decrease of 10.6772 million shares from the previous period. Southern CSI 1000 ETF increased its holdings by 524,400 shares [3]

Core Viewpoint - Jiutian Pharmaceutical announced that both the company and its subsidiaries have no overdue external guarantees, no litigation related to external guarantees, and no losses incurred from being judged against such guarantees [2] Group 1 - The company confirmed the absence of overdue external guarantees [2] - There are no ongoing litigations related to external guarantees [2] - The company has not incurred any losses from judgments related to guarantees [2]

Core Viewpoint - Hunan Jiutian Pharmaceutical Co., Ltd. is focusing on the transformation towards innovative drug development, with a significant increase in R&D investment and a stable operational performance in Q3 2025, despite challenges in the broader pharmaceutical industry [2][3]. Group 1: Q3 Operational Performance - The overall operational status in Q3 2025 remained stable, with market demand relatively consistent and sales progressing as planned [2]. - The pharmaceutical manufacturing industry saw a revenue of 12,275.2 billion yuan in the first half of 2025, a year-on-year decrease of 1.2%, and a profit total of 1,766.9 billion yuan, down 2.8% year-on-year [2]. - Despite industry pressures, the sales of medicated plaster in the terminal market showed a yearly increase, with sales expected to exceed 7 billion yuan in 2024, a growth of approximately 10%, and over 4 billion yuan in the first half of 2025, a growth of about 15% [2]. Group 2: Focus on Innovative Drug Transformation - The company is fully transitioning to focus on innovative drug R&D, with chemical innovative drugs as the core direction and some involvement in traditional Chinese medicine [3]. - Key therapeutic areas include pain management, focusing on polypeptide and small molecule drugs, and oncology, concentrating on PDC drug development [3]. - The company plans to invest between 250 million to 300 million yuan in R&D for 2025, indicating a strong commitment to its innovative transformation [3]. Group 3: Competitive Advantages and Market Strategies - The external pain relief market is expected to grow due to increasing health demands and an aging population, providing significant development space [4]. - The company aims to enhance product strength and brand influence in the gel plaster sector, optimizing product structure to meet diverse health needs [4]. - Specific product strategies include leveraging the advantages of JIJ02 gel for acne treatment and expanding indications in the polypeptide drug field, focusing on pain and pulmonary fibrosis [4]. - To address the impact of centralized procurement on key products like Loxoprofen Sodium Gel, the company plans to enhance sales through a comprehensive channel coverage system, increase R&D investment for new product launches, and strengthen cost control through an integrated supply chain [4].

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-072 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、担保进展情况 近日，九典宏阳因生产经营需要，分别向长沙银行股份有限公司浏阳支行（以 下简称"长沙银行"）、上海浦东发展银行股份有限公司长沙分行（以下简称"浦 发银行"）申请授信。公司与长沙银行签订了《最高额保证合同》，为九典宏阳 提供最高本金余额为人民币 10,000 万元的保证担保；与浦发银行签订了《最高 额保证合同》，为九典宏阳提供最高本金余额为人民币 46,200 万元的保证担保。 以上担保金额在公司已履行审议程序的担保额度以内，无需履行其他审议程 序。本次担保生效后，公司为九典宏阳提供担保的剩余总额度为人民币 23,800 万元整。 三、被担保人情况 公司名称：湖南九典宏阳制药有限公司 统一社会信用代码：91430122344723202P 类型：有限责 ...